Top Institutions in Gynecologic Oncology and Molecular Pathology
Leading institutions employ integrated molecular classification combining immunohistochemistry, targeted next-generation sequencing, and genomic analysis to characterize endometrial carcinomas, with a focus on POLE mutations and ATM protein expression patterns to guide diagnosis and treatment.
-
#1
Memorial Sloan Kettering Cancer Center
New York, NY
MSKCC is a leader in gynecologic cancer research with extensive expertise in molecular classification of endometrial cancer, including POLE mutation analysis and ATM IHC, supported by robust clinical trials and genomic sequencing programs.
Key Differentiators
- Gynecologic Oncology
- Molecular Pathology
- Cancer Genomics
-
#2
Dana-Farber Cancer Institute
Boston, MA
Dana-Farber has a strong translational research program in gynecologic cancers focusing on genomic alterations such as POLE mutations and ATM protein expression, with integrated molecular diagnostics and personalized treatment approaches.
Key Differentiators
- Gynecologic Oncology
- Cancer Genomics
- Molecular Diagnostics
-
#3
MD Anderson Cancer Center
Houston, TX
MD Anderson is recognized for its expertise in gynecologic malignancies and molecular pathology, with significant contributions to understanding the molecular landscape of endometrial cancer including POLE mutations and ATM IHC applications.
Key Differentiators
- Gynecologic Oncology
- Molecular Pathology
- Cancer Genomics
-
#4
Johns Hopkins Hospital
Baltimore, MD
Johns Hopkins has a long-standing reputation in gynecologic oncology research with expertise in molecular markers such as POLE and ATM, contributing to improved diagnostic accuracy and personalized treatment strategies.
Key Differentiators
- Gynecologic Oncology
- Molecular Pathology
- Cancer Research
-
#5
University of California, San Francisco (UCSF) Medical Center
San Francisco, CA
UCSF is known for its innovative research in gynecologic cancers, including molecular profiling of endometrial tumors and development of diagnostic assays such as ATM IHC for identifying POLE mutations.
Key Differentiators
- Gynecologic Oncology
- Molecular Pathology
- Cancer Genomics
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
